401 related articles for article (PubMed ID: 27317091)
1. METastasis Reporting and Data System for Prostate Cancer: Practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer.
Padhani AR; Lecouvet FE; Tunariu N; Koh DM; De Keyzer F; Collins DJ; Sala E; Schlemmer HP; Petralia G; Vargas HA; Fanti S; Tombal HB; de Bono J
Eur Urol; 2017 Jan; 71(1):81-92. PubMed ID: 27317091
[TBL] [Abstract][Full Text] [Related]
2. Rationale for Modernising Imaging in Advanced Prostate Cancer.
Padhani AR; Lecouvet FE; Tunariu N; Koh DM; De Keyzer F; Collins DJ; Sala E; Fanti S; Vargas HA; Petralia G; Schlemmer HP; Tombal B; de Bono J
Eur Urol Focus; 2017 Apr; 3(2-3):223-239. PubMed ID: 28753774
[TBL] [Abstract][Full Text] [Related]
3. Whole-body magnetic resonance imaging (WB-MRI) reporting with the METastasis Reporting and Data System for Prostate Cancer (MET-RADS-P): inter-observer agreement between readers of different expertise levels.
Pricolo P; Ancona E; Summers P; Abreu-Gomez J; Alessi S; Jereczek-Fossa BA; De Cobelli O; Nolè F; Renne G; Bellomi M; Padhani AR; Petralia G
Cancer Imaging; 2020 Oct; 20(1):77. PubMed ID: 33109268
[TBL] [Abstract][Full Text] [Related]
4. Localising occult prostate cancer metastasis with advanced imaging techniques (LOCATE trial): a prospective cohort, observational diagnostic accuracy trial investigating whole-body magnetic resonance imaging in radio-recurrent prostate cancer.
Adeleke S; Latifoltojar A; Sidhu H; Galazi M; Shah TT; Clemente J; Davda R; Payne HA; Chouhan MD; Lioumi M; Chua S; Freeman A; Rodriguez-Justo M; Coolen A; Vadgama S; Morris S; Cook GJ; Bomanji J; Arya M; Chowdhury S; Wan S; Haroon A; Ng T; Ahmed HU; Punwani S
BMC Med Imaging; 2019 Nov; 19(1):90. PubMed ID: 31730466
[TBL] [Abstract][Full Text] [Related]
5. Whole-body MRI-based multivariate prediction model in the assessment of bone metastasis in prostate cancer.
Chen R; Yang Q; Chen W; Yang Y; Cheng C; Sun Y; Lu J
World J Urol; 2021 Aug; 39(8):2937-2943. PubMed ID: 33521882
[TBL] [Abstract][Full Text] [Related]
6. Whole-body magnetic resonance imaging for prostate cancer assessment: Current status and future directions.
Van Nieuwenhove S; Van Damme J; Padhani AR; Vandecaveye V; Tombal B; Wuts J; Pasoglou V; Lecouvet FE
J Magn Reson Imaging; 2022 Mar; 55(3):653-680. PubMed ID: 33382151
[TBL] [Abstract][Full Text] [Related]
7. Multiparametric whole-body 3.0-T MRI in newly diagnosed intermediate- and high-risk prostate cancer: diagnostic accuracy and interobserver agreement for nodal and metastatic staging.
Johnston EW; Latifoltojar A; Sidhu HS; Ramachandran N; Sokolska M; Bainbridge A; Moore C; Ahmed HU; Punwani S
Eur Radiol; 2019 Jun; 29(6):3159-3169. PubMed ID: 30519933
[TBL] [Abstract][Full Text] [Related]
8. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
9.
Dyrberg E; Hendel HW; Huynh THV; Klausen TW; Løgager VB; Madsen C; Pedersen EM; Pedersen M; Thomsen HS
Eur Radiol; 2019 Mar; 29(3):1221-1230. PubMed ID: 30132104
[TBL] [Abstract][Full Text] [Related]
10. Guidelines for Acquisition, Interpretation, and Reporting of Whole-Body MRI in Myeloma: Myeloma Response Assessment and Diagnosis System (MY-RADS).
Messiou C; Hillengass J; Delorme S; Lecouvet FE; Moulopoulos LA; Collins DJ; Blackledge MD; Abildgaard N; Østergaard B; Schlemmer HP; Landgren O; Asmussen JT; Kaiser MF; Padhani A
Radiology; 2019 Apr; 291(1):5-13. PubMed ID: 30806604
[TBL] [Abstract][Full Text] [Related]
11. A Prospective Comparison of
Anttinen M; Ettala O; Malaspina S; Jambor I; Sandell M; Kajander S; Rinta-Kiikka I; Schildt J; Saukko E; Rautio P; Timonen KL; Matikainen T; Noponen T; Saunavaara J; Löyttyniemi E; Taimen P; Kemppainen J; Dean PB; Blanco Sequeiros R; Aronen HJ; Seppänen M; Boström PJ
Eur Urol Oncol; 2021 Aug; 4(4):635-644. PubMed ID: 32675047
[TBL] [Abstract][Full Text] [Related]
12. The Transatlantic Recommendations for Prostate Gland Evaluation with Magnetic Resonance Imaging After Focal Therapy (TARGET): A Systematic Review and International Consensus Recommendations.
Light A; Mayor N; Cullen E; Kirkham A; Padhani AR; Arya M; Bomers JGR; Dudderidge T; Ehdaie B; Freeman A; Guillaumier S; Hindley R; Lakhani A; Pendse D; Punwani S; Rastinehad AR; Rouvière O; Sanchez-Salas R; Schoots IG; Sokhi HK; Tam H; Tempany CM; Valerio M; Verma S; Villeirs G; van der Meulen J; Ahmed HU; Shah TT
Eur Urol; 2024 May; 85(5):466-482. PubMed ID: 38519280
[TBL] [Abstract][Full Text] [Related]
13. Streamlining staging of lung and colorectal cancer with whole body MRI; study protocols for two multicentre, non-randomised, single-arm, prospective diagnostic accuracy studies (Streamline C and Streamline L).
Taylor SA; Mallett S; Miles A; Beare S; Bhatnagar G; Bridgewater J; Glynne-Jones R; Goh V; Groves AM; Janes SM; Koh DM; Morris S; Morton A; Navani N; Oliver A; Padhani AR; Punwani S; Rockall AG; Halligan S
BMC Cancer; 2017 May; 17(1):299. PubMed ID: 28464835
[TBL] [Abstract][Full Text] [Related]
14. Comparison of MRI Sequences in Whole-Body PET/MRI for Staging of Patients With High-Risk Prostate Cancer.
Metser U; Chan R; Veit-Haibach P; Ghai S; Tau N
AJR Am J Roentgenol; 2019 Feb; 212(2):377-381. PubMed ID: 30332285
[TBL] [Abstract][Full Text] [Related]
15. Positron Emission Tomography and Whole-body Magnetic Resonance Imaging for Metastasis-directed Therapy in Hormone-sensitive Oligometastatic Prostate Cancer After Primary Radical Treatment: A Systematic Review.
Farolfi A; Hadaschik B; Hamdy FC; Herrmann K; Hofman MS; Murphy DG; Ost P; Padhani AR; Fanti S
Eur Urol Oncol; 2021 Oct; 4(5):714-730. PubMed ID: 33750684
[TBL] [Abstract][Full Text] [Related]
16. Metastasis Reporting and Data System for Prostate Cancer in Practice.
Padhani AR; Tunariu N
Magn Reson Imaging Clin N Am; 2018 Nov; 26(4):527-542. PubMed ID: 30316465
[TBL] [Abstract][Full Text] [Related]
17. 18F-FDG PET/CT and whole-body MRI diagnostic performance in M staging for non-small cell lung cancer: a systematic review and meta-analysis.
Machado Medeiros T; Altmayer S; Watte G; Zanon M; Basso Dias A; Henz Concatto N; Hoefel Paes J; Mattiello R; de Souza Santos F; Mohammed TL; Verma N; Hochhegger B
Eur Radiol; 2020 Jul; 30(7):3641-3649. PubMed ID: 32125513
[TBL] [Abstract][Full Text] [Related]
18. Innovations in imaging modalities for recurrent and metastatic prostate cancer: a systematic review.
Albisinni S; Aoun F; Marcelis Q; Jungels C; Al-Hajj Obeid W; Zanaty M; Tubaro A; Roumeguere T; De Nunzio C
Minerva Urol Nefrol; 2018 Aug; 70(4):347-360. PubMed ID: 29388415
[TBL] [Abstract][Full Text] [Related]
19. Assessment of whole-body MRI including diffusion-weighted sequences in the initial staging of breast cancer patients at high risk of metastases in comparison with PET-CT: a prospective cohort study.
Hottat NA; Badr DA; Ben Ghanem M; Besse-Hammer T; Lecomte SM; Vansteelandt C; Lecomte SL; Khaled C; De Grove V; Salem Wehbe G; Cannie MM; Jani JC
Eur Radiol; 2024 Jan; 34(1):165-178. PubMed ID: 37555959
[TBL] [Abstract][Full Text] [Related]
20. Whole body MRI (WB-MRI) assessment of metastatic spread in prostate cancer: Therapeutic perspectives on targeted management of oligometastatic disease.
Larbi A; Dallaudière B; Pasoglou V; Padhani A; Michoux N; Vande Berg BC; Tombal B; Lecouvet FE
Prostate; 2016 Aug; 76(11):1024-33. PubMed ID: 27197649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
